Dr. Kannan is a physician scientist with more than 15 years of clinical and translational cancer research experience. He got his PhD in Biochemistry & Molecular Biology from University of North Dakota, Grand Forks, ND, USA, followed by Post Doctoral Fellowship at MD Anderson Cancer Center, Houston, TX, USA. He returned to India to start his own personalized medicine startup, Theranosis Life Sciences Pvt Ltd, incubated at AIC-CCMB, Hyderabad. Oncophenomics Inc, a Delaware C Corp, is a wholly owned subsidiary of the Indian company for entering into global markets. Their primary flagship product is a comprehensive liquid biopsy (CTCs, ctDNA and Exosomes) in vitro diagnostics lab-developed-test for biomarker profiling of common solid tumors such as breast and ovarian cancer with specific focus on immuno-oncology companion diagnostics. Their lab is actively developing custom NGS panels using the Nanopore sequencing platform.
For more information please visit:
https://oncophenomics.com – website under construction
Articles by Shibichakravarthy Kannan
Nanopore is a relatively new sequencing platform and researchers are still trying to optimize the protocol for their own specific applications. In our lab, we work primarily with metagenomic samples and use the 1D sequencing kits. Over the past year, we have optimized this technique. To check the quality of the Nanopore library preparation we…